Psychedelic and ketamine research trials in Turkey
Curated snapshot as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap.
This is a dated selection from the broader clinical catalogue for Turkey, not a complete inventory of research. The catalogue loads separately, may show cached records, and includes compounds and ketamine uses outside this hub's scope. Scope and update timing can produce different totals. Historical publications are separate from these registered-study counts.
6 registered studies are counted in Turkey. By compound: 6 ketamine. By registry status: 1 active, not recruiting, 4 completed and 1 status not reported. By phase: 2 phase 3, 3 phase 4 and 1 not reported. Reported start years run from 2012 (earliest) to 2025 (latest). Studies are linked to 15 source-listed facility records.
Country is taken from the research sites linked to each registry record. A study counts once per country and may appear in several countries. Compound counts may overlap. This directory covers its linked compound hubs; the research map and MCP connector also include other compounds. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Facility records may include aliases or departments of the same institution; they are not a count of unique institutions. A listed facility does not establish a sponsor, lead site or care provider role, or confirm recruitment.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting or not yet recruiting
None of the 6 counted studies in Turkey is listed in the registry as recruiting or not yet recruiting as of 31 October 2026. Status is reported by study teams and can be out of date.
At a glance
- 6 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Ketamine | 6 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Active, not recruiting | 1 | 17% |
| Completed | 4 | 67% |
| Status not reported | 1 | 17% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 3 | 2 | 33% |
| Phase 4 | 3 | 50% |
| Not reported | 1 | 17% |
Registry-listed start years
| Start year | Studies |
|---|---|
| 2024 and later | 1 |
| 2020 to 2023 | 2 |
| 2015 to 2019 | 1 |
| 2010 to 2014 | 2 |
All counted studies
All 6 counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Registry dates | Source-listed facility and city |
|---|---|---|---|---|---|
| Treatment Response In ECT Patients | NCT07463911 | Active, not recruiting | Not reported | Source start: 2025-05-20 (actual)Source date detailsStart: 2025-05-20 (precision: day; source type: ACTUAL; actual) Primary completion: 2027-05-20 (precision: day; source type: ESTIMATED; estimated) Study completion: 2027-05-20 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.566Z; registry revision: 2026-03-13 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Pamukkale University, Denizli |
| A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment | NCT04829318 | Completed | Phase 4 | Source start: 2021-04-26 (actual)Source date detailsStart: 2021-04-26 (precision: day; source type: ACTUAL; actual) Primary completion: 2024-07-22 (precision: day; source type: ACTUAL; actual) Study completion: 2024-07-22 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:15.827Z; registry revision: 2025-09-18 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Hacettepe University Medical Faculty, Ankara; Liv Hospital, Samsun; Erenkoy Mental Health Hospital, Istanbul |
| A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder | NCT04338321 | Completed | Phase 3 | Source start: 2020-08-21 (actual)Source date detailsStart: 2020-08-21 (precision: day; source type: ACTUAL; actual) Primary completion: 2022-01-20 (precision: day; source type: ACTUAL; actual) Study completion: 2022-07-15 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:12.343Z; registry revision: 2025-04-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Hacettepe University Medical Faculty, Ankara; Ege Universitesi Tip Fakultesi, Izmir; Bakirkoy Mental Health Training and Research Hospital, Istanbul; Uskudar University Neuropsychiatry Hospital, Istanbul; Selcuk University Medical Faculty, Konya; Uludag University Medical Faculty, Bursa; Bursa Yuksek Ihtisas Training and Research Hospital, Bursa; Liv Hospital, Samsun; Erenkoy Mental Health Hospital, Istanbul; Namik Kemal University, Tekirdağ |
| 54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide | NCT03097133 | Completed | Phase 3 | Source start: 2017-06-15 (actual)Source date detailsStart: 2017-06-15 (precision: day; source type: ACTUAL; actual) Primary completion: 2019-04-11 (precision: day; source type: ACTUAL; actual) Study completion: 2019-04-11 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:14.289Z; registry revision: 2025-04-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Sisli Etfal Research Training Hospital, Istanbul; Bursa Sevket Yilmaz Research and Training Hospital, Bursa; Uludag University Medical Faculty, Bursa; Samsun Psychiatric Hospital, Samsun |
| Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy | NCT02267980 | Status not reported | Phase 4 | Source start: 2014-07 (type unknown) Saved start 2014-07-01 and reported 2014-07 have different precision. Source date detailsStart: 2014-07 (precision: month; source type: not reported; unknown) Primary completion: 2014-10 (precision: month; source type: ESTIMATED; estimated) Study completion: 2014-10 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:13.506Z; registry revision: 2014-10-20 (precision: day; source type: ESTIMATED; estimated). Source observations do not verify a different saved scalar or establish that an event occurred. | Turgut Ozal Medical Center, Malatya |
| Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy | NCT01870219 | Completed | Phase 4 | Source start: 2012-02 (type unknown) Saved start 2012-02-01 and reported 2012-02 have different precision. Source date detailsStart: 2012-02 (precision: month; source type: not reported; unknown) Primary completion: 2013-04 (precision: month; source type: ACTUAL; actual) Study completion: 2013-05 (precision: month; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:13.146Z; registry revision: 2013-06-06 (precision: day; source type: ESTIMATED; estimated). Source observations do not verify a different saved scalar or establish that an event occurred. | Turgut Ozal Medical Center, Malatya |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
| Condition hub | Studies in this country |
|---|---|
| Depression | 4 |
| Treatment-resistant depression | 2 |
| Bipolar disorder | 1 |
| Suicidal ideation and suicide risk | 1 |
Other country hubs
United States | Canada | Switzerland | United Kingdom | Israel | Brazil | France | China | Netherlands | Germany | Spain | Austria | Australia | Poland | Czech Republic | Ireland | Denmark | Sweden | Taiwan | Argentina | Belgium | Finland | Greece | Hungary | Italy | Mexico | Bulgaria | Egypt | Norway | Pakistan | Portugal